SPPI Spectrum Pharmaceuticals Inc.

9.34
-0.19  -2%
Previous Close 9.53
Open 9.51
Price To Book 3.66
Market Cap 1037206897
Shares 111,049,989
Volume 148,860
Short Ratio
Av. Daily Volume 930,228

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 4Q 2019.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Ongoing.
Poziotinib
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
BLA withdrawn following request from FDA for further manufacturing information - March 15, 2019.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Leucovorin
Peripheral T-Cell Lymphoma cancer

Latest News

  1. The Spectrum Pharmaceuticals (NASDAQ:SPPI) Share Price Has Gained 66% And Shareholders Are Hoping For More
  2. Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9
  3. Why Is Spectrum Pharma (SPPI) Down 1.1% Since Last Earnings Report?
  4. Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
  5. Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
  6. Spectrum Pharma withdraws license application for Rolontis after FDA seeks information on manufacturing
  7. Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)
  8. Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20
  9. Ligand Sells Promacta Rights for $827M, Updates '19 View
  10. Edited Transcript of SPPI earnings conference call or presentation 28-Feb-19 9:30pm GMT
  11. Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio
  12. Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales
  13. Spectrum Pharmaceuticals Inc (SPPI) Q4 2018 Earnings Conference Call Transcript
  14. Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update
  15. Read This Before Buying Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Shares
  16. Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call
  17. Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14
  18. Top 4 Small-Cap Stocks for 2018
  19. Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million